WHO ICTRP trial
ATTR amyloidosis in patients with heart failure with preserved ejection fraction…
NL-OMON49286 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON49286 |
|---|---|
| Public title | ATTR amyloidosis in patients with heart failure with preserved ejection fraction and a cardiac implantable electronic device |
| Scientific title | ATTR amyloidosis in patients with heart failure with preserved ejection fraction and a cardiac implantable electronic device - AMYL-VIP-Device study |
| Primary sponsor | Universitair Medisch Centrum Groningen |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | Protein misfolding disease;10082206;Protein misfolding disease |
| Interventions | ;Amyloidosis;CIED;HFpEF;Wild type |
| Registration date | Apr 21, 2020 |
| Target size | 100 |
| Secondary IDs | NL72578.042.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: